Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Howard L. Kaplan |
Documentos disponibles escritos por este autor (4)
Refinar búsquedaComparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital / Laurie A. Zawertailo en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 3 (Junio)
Título : Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital Tipo de documento: texto impreso Autores: Laurie A. Zawertailo, Autor ; Usoa E. Busto, Autor ; Howard L. Kaplan, Autor Fecha de publicación: 2023 Artículo en la página: pp. 269-280 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Barbitúricos, Comportamiento adictivo, Adicción - psicología, Meprobamato, Trastornos relacionados con sustancias, Triazolam. Resumen: Implementation of regulations to control the prescribing of benzodiazepines in New York State in 1989 resulted in a 55% decrease in benzodiazepine prescribing, with a concomitant increase in the rates of prescribing older sedativehypnotic compounds such as butabarbital (30% increase) and meprobamate (125% increase). Link: ./index.php?lvl=notice_display&id=31023
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 269-280[artículo] Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital [texto impreso] / Laurie A. Zawertailo, Autor ; Usoa E. Busto, Autor ; Howard L. Kaplan, Autor . - 2023 . - pp. 269-280.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 3 (Junio) . - pp. 269-280
Palabras clave: Barbitúricos, Comportamiento adictivo, Adicción - psicología, Meprobamato, Trastornos relacionados con sustancias, Triazolam. Resumen: Implementation of regulations to control the prescribing of benzodiazepines in New York State in 1989 resulted in a 55% decrease in benzodiazepine prescribing, with a concomitant increase in the rates of prescribing older sedativehypnotic compounds such as butabarbital (30% increase) and meprobamate (125% increase). Link: ./index.php?lvl=notice_display&id=31023
Título : Comparative abuse liability of intravenously administered remifentanil and fentanyl Tipo de documento: texto impreso Autores: Godofredo J. Baylon, Autor ; Howard L. Kaplan, Autor ; Gail Somer, Autor Fecha de publicación: 2023 Artículo en la página: pp. 597-606 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Afecto, Opioides, Fentanilo, Piperidinas, Efectos de pupila, Trastornos relacionados con sustancias. Resumen: Remifentanil is a short-acting, esterase-metabolized opioid analgesic. This study compared the abuse liability of remifentanil with that of fentanyl and placebo in a randomized, double-blind, crossover study. Twelve recreational users of opioids received increasing doses of remifentanil (0.6, 1.2, 1.8, 2.4, and 3.0 μg/kg), fentanyl (0.4, 0.8, 1.3, 2.0, 3.0, and 4.5 μg/kg) and placebo via an intravenous infusion pump. Link: ./index.php?lvl=notice_display&id=31149
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 6 (Diciembre) . - pp. 597-606[artículo] Comparative abuse liability of intravenously administered remifentanil and fentanyl [texto impreso] / Godofredo J. Baylon, Autor ; Howard L. Kaplan, Autor ; Gail Somer, Autor . - 2023 . - pp. 597-606.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 6 (Diciembre) . - pp. 597-606
Palabras clave: Afecto, Opioides, Fentanilo, Piperidinas, Efectos de pupila, Trastornos relacionados con sustancias. Resumen: Remifentanil is a short-acting, esterase-metabolized opioid analgesic. This study compared the abuse liability of remifentanil with that of fentanyl and placebo in a randomized, double-blind, crossover study. Twelve recreational users of opioids received increasing doses of remifentanil (0.6, 1.2, 1.8, 2.4, and 3.0 μg/kg), fentanyl (0.4, 0.8, 1.3, 2.0, 3.0, and 4.5 μg/kg) and placebo via an intravenous infusion pump. Link: ./index.php?lvl=notice_display&id=31149
Título : A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam Tipo de documento: texto impreso Autores: Usoa E. Busto, Autor ; Howard L. Kaplan, Autor ; C. Eugene Wright, Autor Fecha de publicación: 2023 Artículo en la página: pp. 628-635 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Afecto, Alprazolam, Ansiolíticos, Bromazepam, Lorazepam, Rendimiento psicomotor. Resumen: Sustained-release (SR) alprazolam may facilitate compliance with oral benzodiazepine treatment of panic disorders that currently requires doses administered three or four times daily. To compare the pharmacokinetic, psychomotor performance, and subjective effects of alprazolam SR (1.5 mg), bromazepam (3 mg taken three times daily), and lorazepam (1 mg taken three times daily), 13 male volunteers (aged 20-45 years) randomly received on four separate occasions one of these medications or placebo. Link: ./index.php?lvl=notice_display&id=31153
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 6 (Diciembre) . - pp. 628-635[artículo] A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam [texto impreso] / Usoa E. Busto, Autor ; Howard L. Kaplan, Autor ; C. Eugene Wright, Autor . - 2023 . - pp. 628-635.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 6 (Diciembre) . - pp. 628-635
Palabras clave: Afecto, Alprazolam, Ansiolíticos, Bromazepam, Lorazepam, Rendimiento psicomotor. Resumen: Sustained-release (SR) alprazolam may facilitate compliance with oral benzodiazepine treatment of panic disorders that currently requires doses administered three or four times daily. To compare the pharmacokinetic, psychomotor performance, and subjective effects of alprazolam SR (1.5 mg), bromazepam (3 mg taken three times daily), and lorazepam (1 mg taken three times daily), 13 male volunteers (aged 20-45 years) randomly received on four separate occasions one of these medications or placebo. Link: ./index.php?lvl=notice_display&id=31153
Título : Inhibition of cytochrome p450 2d6 modifies codeine abuse liability Tipo de documento: texto impreso Autores: Kalyani Kathiramalainathan, Autor ; Howard L. Kaplan, Autor ; Myroslava K. Romach, Autor Fecha de publicación: 2023 Artículo en la página: pp. 435-444 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Codeína, Inhibidores del citocromo P-450 CYP2D6, Inhibidores enzimáticos, Narcóticos, Trastornos relacionados con los opioides, Efectos de la pupila, Quinidina. Resumen: Oral codeine preparations, widely used for analgesia and cough suppression, are abused by some individuals for their mood-altering properties. The enzymatic O-demethylation of codeine is catalyzed by cytochrome P450 2D6 (CYP2D6), leading to the production of metabolites (morphine, morphine-6-glucuronide) that are pharmacologically more potent than codeine. A placebo-controlled, single-blind study was conducted to characterize the subjective effects of codeine associated with abuse liability and to determine the importance of metabolic O-demethylation to codeine abuse liability. Link: ./index.php?lvl=notice_display&id=31180
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 435-444[artículo] Inhibition of cytochrome p450 2d6 modifies codeine abuse liability [texto impreso] / Kalyani Kathiramalainathan, Autor ; Howard L. Kaplan, Autor ; Myroslava K. Romach, Autor . - 2023 . - pp. 435-444.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 4 (Agosto) . - pp. 435-444
Palabras clave: Codeína, Inhibidores del citocromo P-450 CYP2D6, Inhibidores enzimáticos, Narcóticos, Trastornos relacionados con los opioides, Efectos de la pupila, Quinidina. Resumen: Oral codeine preparations, widely used for analgesia and cough suppression, are abused by some individuals for their mood-altering properties. The enzymatic O-demethylation of codeine is catalyzed by cytochrome P450 2D6 (CYP2D6), leading to the production of metabolites (morphine, morphine-6-glucuronide) that are pharmacologically more potent than codeine. A placebo-controlled, single-blind study was conducted to characterize the subjective effects of codeine associated with abuse liability and to determine the importance of metabolic O-demethylation to codeine abuse liability. Link: ./index.php?lvl=notice_display&id=31180
